Business
Faron receives grant from Business Finland
Faron receives grant from Business Finland.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \n \n RNS Number : 4705M\n Faron Pharmaceuticals Oy\n 11 May 2020\n \n \n \n \n Faron Pharmaceuticals Oy\n \n \n (\"Faron\" or the \"Company\")\n \n \n \n \n \n Faron receives €800,000 grant from Business Finland as part of Cancer IO, Finland's leading \n Personalized Health Program\n \n \n - \n Grant will enable state-of-the-art characterization of immunological responses in MATINS trial\n \n - \n Clevegen to be studied in experimental combinations with anti-cancer molecules from other consortium members\n \n \n \n Company announcement, 11 May 2020 at 12.00 PM (EET)\n \n \n \n Inside information\n \n \n \n \n \n \n \n TURKU - FINLAND \n \n - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that it has joined a Finnish consortium, Cancer IO, and received an €800,000 grant from Business Finland to conduct detailed, state-of-the-art characterization of the immunological responses seen in cancer patients in the Company's MATINS trial. \n \n \n \n \n \n The ongoing phase I/II MATINS clinical trial is investigating the tolerability, safety and efficacy of Clevegen, Faron's wholly-owned novel precision cancer immunotherapy targeting Clever-1 positive tumour associated macrophages (TAM), in selected metastatic or inoperable solid tumours.\n \n \n \n \n \n As part of the Business Finland backed initiative, Faron will also study Clevegen in combination with other anti-cancer molecules, in experimental settings together with other consortium members. \n \n \n \n \n \n Cancer IO is a new cancer immunotherapy-focused €10 million top-level collaborative research and innovation project within Business Finland's Personalized Health Program. Coordinated by the University of Helsinki, it integrates immuno-oncology (IO) activities at the universities of Helsinki and Turku, three Finnish university hospitals and one central hospital, eight Finnish SMEs, Finnish cancer patient organizations and nine of the largest IO-investing pharmaceutical companies operating in Finland. Cancer IO has been established to drive the creation of a Finnish IO ecosystem and national IO growth strategy, aiming to provide wealth and well-being through disruptive Nordic IO innovations and better care. Faron's participation in this signific...